This Sources Sought opportunity from Department Of Defense was posted on June 26, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Top

Vela Diagnostics Sequencing System for HIV-1 Genotype Testing

Closed

HT9426-26-RFI-5892Federal

Submission Closed07/09/2026, 03:00:00 PM UTC

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 325413

New

DIBBS

TEST KIT, CHLAMYDIA TRA

Solicitation # SPE2DS-26-T-423P

Solicitation SPE2DS-26-T-423P, issued by the DLA Troop Support Medical Supply Chain, is a request for quotes for one test kit for the detection of Chlamydia trachomatis, identified by NSN 6550-01-725-3600. The kit is designed for in vitro diagnostic use to perform qualitative direct immunofluorescence tests on human urogenital and ophthalmic specimens, as well as for confirming Chlamydia in cell culture. Each kit must provide materials for 50 tests and include two positive control slides, mounting fluid, Chlamydia test reagent, and instructions for use. The required delivery date is September 14, 2026, with the place of performance and delivery located in San Antonio, Texas. The procurement falls under NAICS code 325413 and is subject to destination inspection and acceptance. Packaging must adhere to commercial standards, MIL-STD-2073-1E, and RP001, while marking must comply with Medical Marking Standard No. 1. The contract incorporates various FAR and DFARS clauses, including the Buy American and Balance of Payments Program and the Hazard Communication Standard for hazardous materials. Payment and invoicing are to be processed electronically through the Wide Area WorkFlow system. Quotes must be submitted via the DIBBS portal by September 16, 2026, and the award may be processed through an automated system, with a price evaluation preference applied to HUBZone concerns.

MEDICAL SUPPLY CHAIN MD SURG FSF

POSTED

DEADLINE

TEST KIT, CORONAVIRUS D

Solicitation # SPE2DS-26-T-421Y

Solicitation SPE2DS-26-T-421Y is a fixed-price request for quotations issued by the DLA Troop Support Medical Supply Chain for the procurement of one case of Abbott BinaxNOW COVID-19 Antigen self-test kits for over-the-counter, at-home use. The kits, identified by NSN 6550-01-716-1573, must be delivered to the USNS John L. Canley T-ESB-6 in San Diego, California. Each case contains 12 kits with two tests per kit. The items are subject to a non-extendable shelf life of 12 months, and no more than one month may have elapsed from the date of manufacture to the date of delivery to the government. The contractor must adhere to strict storage and marking requirements, maintaining the kits between 2-30 degrees Celsius and labeling all materials according to Medical Marking Standard No. 1. Packaging must be commercial, utilizing sealed unit containers and suitable exterior shipping containers in accordance with RP001 DLA Packaging Requirements. All labels must include the contract or lot number and the date of manufacture and expiration. Quotes must be submitted via the DIBBS system by September 16, 2026, and the award will be automated. Payment and receiving reports are to be processed electronically through the Wide Area WorkFlow system.

MEDICAL SUPPLY CHAIN MD SURG FSF

POSTED

DEADLINE

Blood Bank Reagents and Consumables Supply

POSTED

DEADLINE

Urine Drug Screening and Confirmation Laboratory Services

Residential Reentry - Co

POSTED

DEADLINE

Intent to Sole Source- Automated Blood Bank Instrumentation

Solicitation # PZIBABPA

The Air Force Life Cycle Management Center intends to award a sole-source, firm-fixed-price Blanket Purchase Agreement to QuidelOrtho Sales Company, LLC. This contract provides automated blood bank instrumentation, reagents, consumables, and associated support for the 88th Medical Group Laboratory Flight at Wright-Patterson Air Force Base. The requirement specifies a fully automated, continuous-access system that integrates with laboratory information systems, including MHS Genesis, to ensure uninterrupted blood bank operations. The decision to sole source follows extensive market research and a Sources Sought notice, which determined that QuidelOrtho is the only available source capable of meeting the minimum technical requirements. These requirements include specific methodology, FDA-approved reagent kits, and a single-platform solution for blood bank testing. The procurement falls under NAICS code 325413. Interested parties wishing to challenge the sole-source intent must submit a detailed capability statement to the designated points of contact by September 22, 2026.

POSTED

DEADLINE

Supplier of I-STAT PT Plus Control Reagent Level 2

MEDICAL SUPPLY CHAIN MD SURG FSF

POSTED

DEADLINE

CONTROL, BLOOD CHEMISTR

Solicitation # SPE2DS-26-T-415T

This contract is for the procurement of one box of PT Plus Control Reagent Level 2, used for coagulation testing with the i-STAT PT Plus cartridge on the i-STAT 1 Government Field Kit analyzer. The item is issued in boxes containing ten 1.0ml units and is identified by NSN 6550-01-725-6872. Delivery is required within 20 days after the order is placed. The reagent has a non-extendable shelf life of 12 months, and no more than one month may elapse between the date of manufacture and delivery to the government. Storage requires refrigeration between 2 to 8 degrees Celsius, and the product must not be frozen. All supplies must adhere to DLA packaging and medical marking standards, including specific labeling for manufacture and expiration dates, contract numbers, and lot numbers.

MEDICAL SUPPLY CHAIN MD SURG FSF

POSTED

DEADLINE

CONTROL, BLOOD CHEMISTR

Solicitation # SPE2DS-26-T-415M

This contract is for the procurement of one box of i-STAT PT Plus Control Reagent Level 1, used for coagulation testing on the i-STAT 1 Government Field Kit blood gas analyzer. Each box contains ten 1.0 ml units. The item is subject to a non-extendable shelf life of 12 months, with a requirement that no more than one month passes between the date of manufacture and the date of delivery to the government. Proper refrigeration is required for storage between 2 to 8 degrees Celsius. The supplier must adhere to DLA packaging and medical marking standards, ensuring each unit is sealed and protected in commercial shipping containers. All labels must clearly state the contract number, lot number, and dates of manufacture and expiration. Delivery is required within 20 days after the order is placed. Bidders are required to specify the source and part number being supplied.

MEDICAL SUPPLY CHAIN MD SURG FSF

POSTED

DEADLINE

Solicitation # SPE2DS-26-T-409W

This contract is for the procurement of one benzene chip designed for use with a CMS analyzer. The chip features ten measurement capillaries filled with a substance-specific reagent system, providing a measuring range of 0.5 to 10.0 ppm and a total capacity of ten tests. The item is identified by NSN 6550-01-530-9389 and must be delivered within 20 days after the order is placed. The product is subject to a non-extendable shelf life of 24 months, with a requirement that no more than three months elapse between the date of manufacture and the date of delivery to the government. Packaging must meet commercial standards and be secured in sealed unit containers to prevent damage. All labeling and marking must comply with Medical Marking Standard No. 1, including the date of manufacture, expiration or retest date, and the contract or lot number.

MEDICAL SUPPLY CHAIN MD SURG FSF

POSTED

DEADLINE

TEST KIT, BACTERIA DETE

Solicitation # SPE2DS-26-T-410L

This solicitation, issued by the Department of Defense Medical Supply Chain, is for the procurement of four packages of Pathogel bacteria determination test kits under solicitation number SPE2DS-26-T-410L. These single-use, self-contained kits utilize a selective medium and special gelling agent to detect coliform, E. coli, and hydrogen sulfide producing enterobacteriaceae, such as Salmonella and Citrobacter, in food, beverages, and water. The kits provide results within 28 hours and are capable of detecting 1CFU per 100ml in water and 1CFU per 3ml in juice. Each package contains 25 units. The contract specifies a non-extendable shelf life of six months, requiring that no more than one month has elapsed from the date of manufacture to the date of delivery. Items must be stored and shipped between 15 and 25 degrees Celsius and must adhere to Medical Marking Standard No. 1 and DLA packaging requirements. Delivery is required within 20 days after receipt of the order for the place of performance at Fort Riley. Bidders are required to specify the source and part number being supplied for NSN 6550-01-723-3649.

MEDICAL SUPPLY CHAIN MD SURG FSF

POSTED

DEADLINE

Cepheid Reagents and Consumables BPA

Solicitation # 246-26-Q0040

The Indian Health Service Lawton Service Unit is establishing a Blanket Purchase Agreement for molecular diagnostic reagent test kits, cartridges, and consumables specifically for the Cepheid GeneXpert Analyzer. This combined solicitation, identified as 246-26-Q0040, is set aside for Indian Small Business Economic Enterprises under NAICS code 325413. The contract is structured as an IDIQ agreement consisting of a base year and four option years, with performance taking place in Lawton, Oklahoma. The scope of work includes the provision of reagent items based on estimated annual volumes and requires strict adherence to FDA regulations and CLIA 88 standards. Eligible offerors must provide self-certification of their status as an Indian Economic Enterprise via the Buy Indian Act representation form. The response deadline for this requirement is September 14, 2026, with the primary point of contact being Audrey Yackeyonny.

Indian Health Service

POSTED

DEADLINE

First To Know® Syphilis Rapid Test Kit Supply

PROC OA DIVISION OF PURCHASING PROCUREMENTS

POSTED

4 days ago

DEADLINE

in 6 days

AI Contract Overview

The Walter Reed Army Institute of Research, through the Defense Health Agency Contracting Activity, is conducting market research via a Request for Information and Sources Sought notice to assess the availability of commercial vendors capable of providing a Vela Diagnostics Sentosa sequencing system for HIV-1 genotype testing, including all required sub-system components, maintenance, repair, and operational consumables. This system is critical for the HIV Diagnostics and Reference Lab at WRAIR to monitor drug resistance mutations in HIV-1 infected personnel and beneficiaries, and the requirement is strictly brand-specific to the Vela Sentosa SQ301 instrument, Sentosa SX101 pipetting system, and associated FDA-approved reagents and kits that meet College of American Pathologists clinical standards. All responses must demonstrate compliance with Minimum Essential Characteristics, which mandate one-year shelf life for reagents, four-month shelf life for positive controls, delivery of consumables within 60 to 90 days of request, and vendor response to equipment failures within 48 to 72 hours. Vendor personnel must possess Real ID credentials to access military installations for maintenance. The NAICS code for this requirement is 325413, and respondents must be registered in SAM.gov with a valid Unique Entity ID and list all authorized government ordering vehicles such as OMNIBUS IV, CHESS, or GSA contracts. Responses must be submitted electronically via email to the designated contracting points of contact no later than 11:00 a.m. EST on July 9, 2026, and are limited to three pages total in 12-point font using Microsoft Word or Adobe PDF formats. Submissions must include a cover page with organization details, technical and administrative contacts, topic areas addressed, SAM.gov registration confirmation with UEI, and a list of authorized ordering vehicles. Respondents must also provide a capabilities statement that clearly demonstrates alignment with the MECs, supported by sufficient technical data, and indicate whether similar products or services are sold commercially to the general public. No pricing, contract clauses, or evaluation criteria are included in this notice, as it is a pre-solicitation market research tool with no obligation for the government to award a contract. The government will not reimburse any costs associated with responding, and no evaluation results will be provided. All information marked as proprietary will be treated as confidential. This RFI does not constitute a solicitation, and any future acquisition will be announced via a separate formal solicitation.

General Info

Vela Diagnostics Sentosa system requested for HIV-1 testing, FDA-approved, CAP-accredited, no contract awarded, responses due July 9, 2026.

Agency

Department Of Defense → Army Medical Resources Acq ActivityView Agency

NAICS

325413 - In-Vitro Diagnostic Substance ManufacturingView NAICS

Place of Performance

Silver Spring, MD, 20910, USA

Set-Aside

NONE

Documents

(1)

Minimum Essential Characteristics for Vela Diagnostics Sequencing System

PDF•sow

AI Contract Breakdown

Uniform Contract Format

Timeline

PhaseClosed

PostedJun 26

Sources Sought

Response DeadlineJul 9

Deadline has passed

Submission Closed

07/09/2026, 03:00:00 PM UTC

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

AgencyDepartment Of Defense → Army Medical Resources Acq Activity

Contacts2 people available

OfficeFORT DETRICK, MD, 21702, USA

Organization / Agency

Department Of Defense → Army Medical Resources Acq Activity

View Agency Profile

Office AddressFORT DETRICK, MD, 21702, USA

Contacts

Brenda Mena

contact@example.gov

Lance Nowell

contact@example.gov

Full Description

Request for Information (RFI) /Sources Sought (SS) Notice

RFI Number: HT9426-26-RFI-5892

Requiring Activity Name: The Walter Reed Army Institute of Research (WRAIR)

Contracting Office: Defense Health Agency Contacting Activity (DHACA)

Subject: WRAIR has a need for a Vela Diagnostics sequencing system (Brand name only) for HIV-1 genotype testing to include all required sub-system components, maintenance and repair, and operational supplies and consumable products.

Place of Performance or Delivery: Silver Spring, MD 20910

General Information:

In accordance with Revolutionary FAR Overhaul (RFO) 15.101; Exchange with industry before receipt of proposals, this Sources Sought is for information and planning purposes only and at this time shall not be construed as a solicitation or as an obligation or commitment on the part of the Government nor will the Government pay for information solicited. Responses to this notice are not offers and cannot be accepted by the Government to form a binding contract. Responders are advised that the United States Government will not pay for any information or administrative costs incurred in response to this RFI. All costs associated with responding to this RFI/SS will be solely at the interested responder’s expense. Not responding to this RFI/SS does not preclude participation in any future Request for Proposal, if any is issued. No evaluation letters and/or results will be issued to Responders responding to this RFI/SS.

This Sources Sought Notice is a Market Research tool used to determine the availability and adequacy of potential sources, prior to determining the method of acquisition and issuance of a solicitation.

The NAICS code for this requirement is: 325413 - In-Vitro Diagnostic Substance Manufacturing

DISCLAIMER: This Request for Information (RFI)/Sources Sought (SS) Notice is NOT a Request for Proposals (RFP) or a Request for Quotations (RFQ). This RFI is issued solely for market research information and planning purposes only and does not constitute a solicitation.

Responses to the RFI will not be returned. Neither unsolicited proposals nor any other kind of offers will be considered in response to this RFI. Responses to this notice are not offers and cannot be accepted by the Government to form a binding contract. No contract will be awarded from this announcement. No reimbursement will be made of any costs to provide information in response to this announcement or any follow-up information requests; responders are solely responsible for all expenses associated with responding to this RFI. Availability of any formal solicitation will be announced under a separate announcement.

All information received in response to this RFI will be treated as confidential business information. Submitters should properly mark their responses if the information is confidential. All information received in response to this RFI that is marked Proprietary, will be handled accordingly.

At this time, questions concerning the composition and requirements for future solicitation will not be entertained.

RFI Response and due date: 11:00am EST on 09 July 2026

Instructions to Responders:

Responses from all capable and qualified sources are encouraged to respond to this request.

Review the attached Minimum Essential Characteristics (MECs) . Respondents should address how they best can fulfil the requirements set forth in the MECs in their capabilities statement. Capability Statements or any other proprietary information relative to this RFI should adhere to the following formatting and outline instructions:

White papers should adhere to the following formatting and outline instructions:

1. All submissions shall be made electronically and be in one of the following formats: Microsoft Word or Adobe PDF.

2. Cover Page (1page)

Title
Organization
Responders technical and administrative points of contact (names, addresses, phone, fax number and email addresses)
Topic area(s) addressed
Respondents shall be registered in www.sam.gov under the NAICS code of 325413 System for Award Management (SAM.gov) Unique Entity ID (UEI)
List all ordering vehicles held by respondents in which you are an authorized third-party vendor. Please include associated contract numbers (e.g. OMNIBUS IV,CHESS, GSA, etc.)

3. Interested parties are asked to respond to this RFI and submit a capabilities statement that supports the focus of this RFI. Please review the place of performance requirements. Please submit written responses via email in Microsoft Office 2000 or later format. All responses should be complete: in 12-point font; and not to exceed 3 pages total, including graphics, tables, and appendices.

Response shall address whether the respondent is offering similar or like supplies/services in the commercial market to the general public.

Please note that the response shall provide sufficient technical data to determine how you fully meet the requirements as specified in the MECs.

The requested information shall be submitted by the date and time specified above, via email, to the Contract Specialist Brenda Mena at email: brenda.i.mena.civ@health.mil and Contracting Officer, Lance Nowell at email: lance.l.nowell.civ@health.mil. Only electronic responses will be accepted. No evaluation letters and/or results will be issued to the respondents. Currently no solicitation exists; therefore, a copy of the solicitation cannot be provided. Telephone requests will not be honored, and no bidders list shall be maintained. No inquiries regarding any potential future acquisition activities shall be entertained.

BACKGROUND

This requirement is for Vela Sentosa sequencer kits, consumables, supplies, sequencing systems and sub-components, and maintenance and repair (name brand only) for HIV-1 genotype testing as specified in the Minimum Essential Characteristics (MECs). The HIV Diagnostics and Reference Lab (HDRL), Diagnostics and Countermeasures Branch (DCB) at the Walter Reed Army Institute of Research (WRAIR) currently utilizes the Vela Sentosa SQ Next Generation Sequencing (NGS) system in order to perform HIV genotype testing which is critical for the monitoring of drug resistance mutations in HIV-1 infected soldiers and their beneficiaries. The Vela Sentosa NGS system includes instrumentation and reagents required to perform the Vela Sentosa SQ HIV-1 Genotype test in a College of American Pathologist (CAP) accredited laboratory. As the system and assay is Food and Drug Administration (FDA) approved, clinical testing laboratories are required to use the instruments and reagents approved by the FDA in the execution of the test.